The Sell Now Lab

The Outlier Trap: Why One Big Customer Is Not a Market

cmorrison@viaverus.com (Chris Morrison) — Thu, 07 May 2026 21:10:54 GMT

How a single marquee partner can convince you that you have validation when what
you have is a coincidence

Every founder of a disruptive technology company will, at some point, get the phone call. A name-brand company — a Merck, a Google, a J.P. Morgan, a Mayo Clinic — has decided to engage. They want to pilot the product. They are willing to invest. They are willing to co-publish. They are willing, in some cases, to put non-trivial money on the table. The temptation in that moment is enormous, and it is also dangerous. Because what feels like the launchpad of a rocket ship is, more often than not, an outlier wearing the costume of a market signal.

One innovator is not a market. One innovator is a coincidence with a logo.

Anatomy of the trap

Diagnostic Biochips, a neurotechnology company, lived through this exact scenario. The team had spent years building best-in-class implantable sensors for in vivo neuroscience research. As they considered their next act — moving into preclinical drug discovery via brain organoid measurement — Merck stepped forward. As a customer and partner. They invested in discovery, contributed biology expertise, and co-published the science. By any reasonable measure, this looked like the kind of validation founders dream of.

The natural conclusion was the obvious one: we have a Merck, so let's go get two or three more Mercks. This is the moment, in retrospect, when the company could very easily have ended its own story. Because had the team accepted that conclusion at face value, they would have built an entirely different — and entirely wrong — product.

What the conventional path would have looked like

If the Merck signal had been treated as market validation, the next move would have been to scale to a high-throughput screening instrument. Ninety-six wells minimum, perhaps more. Industrial-grade automation. The kind of capital equipment that big pharma discovery groups deploy at scale. The team would have raised a substantial round to fund that build, hired aggressively against it, and shipped a product that — based on what they later learned — almost no other pharma company in the world was ready to buy.

That is the Innovation Death Spiral in slow motion. A single outlier signal interpreted as a market signal, an enormous capital deployment against that signal, and twelve to eighteen months later a sales team with a beautiful product and no buyers. The graveyard of innovation is full of companies that built the right product for the wrong customer, then ran out of cash before they could course correct.

The intervention: skepticism as discipline

The Sell Now™ Sales Playbook is built on a foundational principle from the Cynefin framework: in a complex domain, you do not plan and execute, you probe and learn. The role of leadership is to keep the team in discovery mode, not to push them into execution mode prematurely. When a Merck-sized signal arrives, the disciplined response is not “let's get more,” it is “let's go find out whether this is a pattern or an exception.”

In DBC's case, that meant systematic customer discovery across the rest of pharma — dozens of conversations with discovery groups, assay development teams, and translational researchers. The hypothesis under test was simple: are there other Mercks out there, ready to engage at a similar level? The answer, after dozens of interviews, was unambiguous. Merck was a true outlier. No one else in pharma was at that level of readiness. Not even close.

That answer would have been devastating if the team had already raised a round and built the high-throughput screening instrument. Instead, because the discovery happened before the commitment, it was simply useful information. The Merck partnership was preserved. The relationship continued to produce real value. But the product roadmap — and, critically, the go-to-market strategy — pivoted to fit the market that actually existed.

Three signals that should put you in discovery mode, not execution mode

1. The marquee customer arrived through a relationship channel, not through a marketing channel. If your first big customer came through a personal introduction, an academic collaboration, or a mutual investor, that is not a sales process. That is a network. Networks do not scale.

2. The customer's internal champion is unusual. If your buyer is the rare individual at their organization who is willing to take risks on emerging technology, you have signal about that individual, not about that industry. Find out how many other people in their company think the way they do. Often, the answer is none.

3. The deal economics are non-standard. Co-development agreements, joint research grants, and equity-flavored partnerships look like sales but behave like partnerships. They tell you that this customer values you. They do not tell you what your product would be worth in an arms-length transaction with the next ten buyers.

What to do instead

The discipline is to treat your first marquee customer as a hypothesis generator, not a market thesis. Use the relationship to learn — about the buying process, the technical objections, the integration challenges, the organizational dynamics. Use the access to validate or invalidate the broader market assumption. The question you are trying to answer is not “how do we get more customers like this one?” The question is “does the rest of this market exist at all, and if it does, what does it actually look like?”

In DBC's case, the answer to that question turned out to be surprising — and far more valuable than another Merck would have been. The real market was not the one they had assumed. There was a translational research segment sitting between basic academic neuroscience research and pharma discovery, and that segment was ready to buy now. That is the subject of another post in this series.

The Merck-shaped success story you are about to chase may be the most expensive coincidence of your career. Test it before you bet on it.

The practical takeaway

If you have a marquee customer and you are tempted to scale against them, slow down for ninety days. Run thirty to fifty structured customer discovery conversations across the rest of the segment. If you find the pattern, scale with confidence — you have just discovered a market. If you do not find the pattern, you have just saved your company. Either outcome is worth the time.

If You're Launching Without Paying Customers, You're Already Too Late

cmorrison@viaverus.com (Chris Morrison) — Thu, 07 May 2026 20:45:34 GMT

Why the day of your “big launch” is the worst possible day to start selling

There is a particular kind of product launch story that I have watched play out, with grim regularity, for the better part of three decades. It opens with a press release, a polished website, a booth on the trade show floor, and a sales team handed a quota and a slide deck. Six months later, the deck has been revised four times, the quota has been missed three quarters in a row, and the executive team is quietly being replaced. The product was not bad. The market was not absent. The launch itself was the problem.

This pattern is so common that the Sell Now™ Sales Playbook has a name for it: the Innovation Death Spiral. Roughly 90% of startups fail within five years, and 90% of those failures trace to market development risk, not product risk. Premature scaling — pouring sales and marketing dollars into a process that has never been validated — is the key mistake for 70% of new venture failures. And yet the default playbook for most disruptive launches is, essentially: build the product, hire the salespeople, throw the launch party, and hope.

If your first paying customer arrives after launch day, you have not launched. You have placed a very expensive bet.

The conventional launch is a bet, not a strategy

The reason conventional launch playbooks fail for disruptive products is structural. Methodologies like SPIN, Challenger, and Customer-Centric Selling all assume one thing: that a repeatable sales process already exists, and the job of the team is to execute it. For an incremental product or a line extension, that assumption holds. There is enough adjacent data — comparable products, comparable buyers, comparable cycles — to build a plan with reasonable confidence.

For a disruptive product, none of that exists. By definition, you are doing something for the first time. The buyer profile, the value proposition, the messaging that actually resonates, the lead-gen channel that actually converts, the install and adoption process — every one of these is a hypothesis. Asking a professional sales team to execute a sales process that has not yet been discovered and codified is like handing a carpenter a blueprint and forgetting the hammer. They will fail, and it will not be their fault.

What “paying customers before launch” actually means

The fix is not to skip the launch. The fix is to start selling — really selling, with real money on the table — long before the launch. In a recent LinkedIn Live conversation, Brian Jamison, CEO of Diagnostic Biochips, walked through exactly what this looked like for his company. DBC was developing a new instrument for the brain organoid research market, a category that, frankly, did not yet exist as a commercial market. The conventional path would have been to build the commercial unit, polish it, and unveil it at the Society for Neuroscience conference.

They did not do that. Instead, the team placed pre-commercial prototypes with a small set of qualified early-access customers — and charged them. Not full retail. Roughly half-price for a product they openly described as a beta. They wrote checks. They signed POs. Some used rental terms. The cash was real, and that changed everything.

Why money is the only honest market signal

Customer interviews are useful. Surveys are useful. Industry reports are useful. None of them are real. The Sell Now™ Playbook puts it bluntly: data quality runs from low integrity (internal assessment), to critical insights (customer discovery), to real (actually selling). The first time a prospect writes you a check is the first time you have unambiguous data about whether you have a market.

Free pilots, free trials, free POCs — these all generate something that looks like demand but is actually polite curiosity. People will accept free things they have no intention of buying. They will sit through your demo to be helpful. They will praise your product to your face and never speak of it again. Money cuts through all of that. When someone agrees to pay, even at a steep discount, even for a beta, they are telling you something true about the value you create.

What this means for your launch plan

If you are 12 to 18 months from launch, the practical implications are concrete. First, do not wait until your commercial product is ready to start selling. Start now, with whatever version of the product you can put in a customer's hands. Second, charge for it. Discount aggressively, structure flexible payment terms, do whatever you need to do — but do not give it away. Third, treat the period before your formal launch as your most important sales period, not your warm-up act.

By the time DBC arrived at SFN — six months before their commercial product was actually shipping — they were not unveiling a product. They were taking pre-orders against a pipeline they had been building for a year. They walked away from that one conference with 180 marketing-qualified leads, multiple early-access customers already converted, and a real PO for a commercial unit. None of it was theater. All of it was selling.

The harder question

The challenge is not technical. The framework is straightforward, the practices are documented, and the tools are available. The challenge is psychological. Selling before you have a finished product feels uncomfortable. Charging for a beta feels presumptuous. Asking customers to pay you for the privilege of helping you finish your product feels backwards. These instincts are exactly what the Innovation Death Spiral feeds on.

If you are within sight of your launch and you do not yet have paying customers, you do not have a launch problem. You have a market validation problem dressed up as a launch problem. The good news is that the longer your runway, the more time you have to fix it. The bad news is that every month you wait is a month of resources you cannot recover. Start selling now.